Skip to main content
Top
Published in: Clinical Rheumatology 4/2017

01-04-2017 | Original Article

Circulating Dickkopf-1 and sclerostin in patients with Paget’s disease of bone

Authors: Luca Idolazzi, Angelo Fassio, Gaia Tripi, Vania Braga, Ombretta Viapiana, Giovanni Adami, Maurizio Rossini, Davide Gatti

Published in: Clinical Rheumatology | Issue 4/2017

Login to get access

Abstract

Paget disease of bone is a chronic metabolic bone disorder characterized by increased bone resorption and new bone formation. The aim of this study is defining the role of inhibitors of canonical Wnt/b-catenin signaling pathway in patients with Paget disease of bone. Scarce and contrasting results have been reported in literature. We studied 40 patients (15 females and 25 males) with radiological and scintigraphic evidence of Paget disease of bone and 40 healthy subjects matched by age and sex. N-propeptide of type I collagen, C-terminal telopeptide of type I collagen, sclerostin, and Dickkopf-related protein 1 (DKK1) were evaluated by blood samples in our laboratory. As expected, mean serum levels of bone turnover markers (N-propeptide of type I collagen and C-terminal telopeptide of type I collagen) were significantly higher in the Paget disease of bone group compared with the control group. No difference was observed between groups in Dickkopf-1 and sclerostin. Dickkopf-1 and sclerostin were never correlated with each other or with bone turnover markers. Sclerostin was positively correlated with age. In conclusion, our results suggest that the regulators of the Wnt-β catenin pathway are not altered in patients with Paget disease of bone. The positive correlation we found between sclerostin and age in Paget disease of bone patients indicates that in comparative studies, sclerostin serum levels must be adjusted for age.
Literature
2.
go back to reference Ralston SH, Langston AL, Reid IR (2008) Pathogenesis and management of Paget’s disease of bone. Lancet 372(9633):155–163CrossRefPubMed Ralston SH, Langston AL, Reid IR (2008) Pathogenesis and management of Paget’s disease of bone. Lancet 372(9633):155–163CrossRefPubMed
3.
go back to reference Vega D, Maalouf NM, Sakhaee K (2007) Clinical review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92(12):4514–4521CrossRefPubMed Vega D, Maalouf NM, Sakhaee K (2007) Clinical review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92(12):4514–4521CrossRefPubMed
4.
go back to reference Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148(6):2635–2643CrossRefPubMed Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148(6):2635–2643CrossRefPubMed
5.
go back to reference Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ et al (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17(10):1231–1234CrossRefPubMed Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ et al (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17(10):1231–1234CrossRefPubMed
6.
go back to reference Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17(10):1235–1241CrossRefPubMedPubMedCentral Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17(10):1235–1241CrossRefPubMedPubMedCentral
7.
go back to reference Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6(10):e25900CrossRefPubMedPubMedCentral Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6(10):e25900CrossRefPubMedPubMedCentral
8.
go back to reference Fujita K, Janz S (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6:71CrossRefPubMedPubMedCentral Fujita K, Janz S (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6:71CrossRefPubMedPubMedCentral
9.
go back to reference Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C et al (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33(1):77–83PubMed Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C et al (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33(1):77–83PubMed
10.
go back to reference Rossini M, Adami S, Zanotti R, Viapiana O, Idolazzi L, Biondan M et al (2014) Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 133(3):933–935CrossRefPubMed Rossini M, Adami S, Zanotti R, Viapiana O, Idolazzi L, Biondan M et al (2014) Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 133(3):933–935CrossRefPubMed
11.
go back to reference Gatti D, Rossini M, Viapiana O, Povino MR, Liuzza S, Fracassi E et al (2013) Teriparatide treatment in adult patients with osteogenesisimperfecta type I. Calcif Tissue Int 93(5):448–452CrossRefPubMed Gatti D, Rossini M, Viapiana O, Povino MR, Liuzza S, Fracassi E et al (2013) Teriparatide treatment in adult patients with osteogenesisimperfecta type I. Calcif Tissue Int 93(5):448–452CrossRefPubMed
12.
go back to reference Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S et al (2013) Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 92(4):324–329CrossRefPubMed Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S et al (2013) Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 92(4):324–329CrossRefPubMed
13.
go back to reference Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93(2):121–132CrossRefPubMed Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93(2):121–132CrossRefPubMed
14.
go back to reference Tomei P, Zaza G, Granata S, Gatti D, Fraccarollo C, Gesualdo L et al (2014) Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients. Transplant Proc 46(7):2241–2246CrossRefPubMed Tomei P, Zaza G, Granata S, Gatti D, Fraccarollo C, Gesualdo L et al (2014) Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients. Transplant Proc 46(7):2241–2246CrossRefPubMed
15.
go back to reference Radetti G, Franceschi R, Adami S, Longhi S, Rossini M, Gatti D (2014) Higher circulating parathormone is associated with smaller and weaker bones in obese children. Calcif Tissue Int 95(1):1–7CrossRefPubMed Radetti G, Franceschi R, Adami S, Longhi S, Rossini M, Gatti D (2014) Higher circulating parathormone is associated with smaller and weaker bones in obese children. Calcif Tissue Int 95(1):1–7CrossRefPubMed
16.
go back to reference Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96(5):1555–1559CrossRefPubMed Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96(5):1555–1559CrossRefPubMed
17.
go back to reference Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3):739–742CrossRefPubMed Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3):739–742CrossRefPubMed
18.
go back to reference Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR et al (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 27(11):2259–2263CrossRefPubMed Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR et al (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 27(11):2259–2263CrossRefPubMed
19.
go back to reference Gatti D, Viapiana O, Idolazzi L, Fracassi E, Ionescu C, Dartizio C et al (2014) Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. Bone 67:189–192CrossRefPubMed Gatti D, Viapiana O, Idolazzi L, Fracassi E, Ionescu C, Dartizio C et al (2014) Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. Bone 67:189–192CrossRefPubMed
20.
go back to reference Beauregard M, Gagnon E, Guay-Bélanger S, Siris ES, Morissette J, Brown JP et al (2013) Genetic association study of Dickkopf-1 and sclerostin genes with Paget disease of bone. Calcif Tissue Int 93(5):405–412CrossRefPubMed Beauregard M, Gagnon E, Guay-Bélanger S, Siris ES, Morissette J, Brown JP et al (2013) Genetic association study of Dickkopf-1 and sclerostin genes with Paget disease of bone. Calcif Tissue Int 93(5):405–412CrossRefPubMed
21.
go back to reference Yavropoulou MP, van Lierop AH, Hamdy NAT, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51(1):153–157CrossRefPubMed Yavropoulou MP, van Lierop AH, Hamdy NAT, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51(1):153–157CrossRefPubMed
22.
go back to reference Polyzos SA, Anastasilakis AD, Litsas I, Sapranidis M, Efstathiadou Z, Kita M et al (2010) Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget’s disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. J Clin Densitom 13(2):190–196CrossRefPubMed Polyzos SA, Anastasilakis AD, Litsas I, Sapranidis M, Efstathiadou Z, Kita M et al (2010) Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget’s disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. J Clin Densitom 13(2):190–196CrossRefPubMed
23.
go back to reference Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MWJ (2009) Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem 42(10–11):965–969CrossRefPubMed Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MWJ (2009) Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem 42(10–11):965–969CrossRefPubMed
24.
go back to reference Albagha OME, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML et al (2011) Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 43(7):685–689CrossRefPubMed Albagha OME, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML et al (2011) Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 43(7):685–689CrossRefPubMed
25.
go back to reference Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2011) Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. National Academies Press (US), Washington (DC) Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2011) Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. National Academies Press (US), Washington (DC)
26.
go back to reference Kuipers AL, Zhang Y, Yu S, Kammerer CM, Nestlerode CS, Chu Y et al (2014) Relative influence of heritability, environment and genetics on serum sclerostin. Osteoporos Int 25(3):905–912CrossRefPubMed Kuipers AL, Zhang Y, Yu S, Kammerer CM, Nestlerode CS, Chu Y et al (2014) Relative influence of heritability, environment and genetics on serum sclerostin. Osteoporos Int 25(3):905–912CrossRefPubMed
Metadata
Title
Circulating Dickkopf-1 and sclerostin in patients with Paget’s disease of bone
Authors
Luca Idolazzi
Angelo Fassio
Gaia Tripi
Vania Braga
Ombretta Viapiana
Giovanni Adami
Maurizio Rossini
Davide Gatti
Publication date
01-04-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3497-1

Other articles of this Issue 4/2017

Clinical Rheumatology 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.